Doer Biologics Begins Phase 2 Dosing of DR10624 for Severe Hypertriglyceridemia

HANGZHOU, China, Sept. 30, 2024-- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company specializing in innovative treatments for metabolic diseases and cancers, has announced a significant milestone. The company has completed the initial patient dosing in its Phase 2 clinical trial for DR10624, a novel tri-specific agonist targeting the Fibroblast Growth Factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR). The trial aims to evaluate the efficacy and safety of DR10624 for patients suffering from severe hypertriglyceridemia (SHTG).

Severe hypertriglyceridemia is characterized by unusually high levels of triglycerides in the blood, posing increased risks for acute pancreatitis and atherosclerotic cardiovascular disease (ASCVD). The Phase 2 study, which is randomized, placebo-controlled, and double-blind, will assess three different dose levels of DR10624 in adult patients with fasting triglyceride levels equal to or exceeding 5.65 mmol/L (500 mg/dL) at the time of screening. The trial will involve a total of 72 participants.

Yanshan Huang, Ph.D., the founder and Chief Executive Officer of Doer Bio, emphasized the unique nature of DR10624: "This first-in-class, long-acting tri-agonist was developed using our proprietary MultipleBody® platform technology. It has been engineered to display balanced activity for treating metabolic diseases. In non-clinical studies, DR10624 has shown exceptional potency in reducing body weight, lowering triglycerides, normalizing blood lipids, and improving liver function."

Yongliang Fang, Ph.D., Chief Operating Officer of Doer Bio, expressed enthusiasm about the progression of their research: “We are thrilled to announce the dosing of the first patient in our Phase 2 study of DR10624 for the treatment of severe hypertriglyceridemia. Patients with uncontrolled hypertriglyceridemia are at a significantly higher risk of developing acute pancreatitis and ASCVD. This Phase 2 study is meticulously designed to identify the optimal dose for future Phase 3 clinical trials. We are committed to advancing DR10624 as a potential treatment option for patients battling SHTG.”

About Doer Bio:
Zhejiang Doer Biologics Co., Ltd. ("Doer Bio") is a clinical-stage biopharmaceutical company dedicated to the discovery and development of multi-domain, multi-specific biotherapeutics. These innovations aim to address significant unmet medical needs in the fields of metabolic diseases and cancers. The company has developed several proprietary platform technologies, including xLONGylation®, MultiBody®, AccuBody®, and SMART-VHHBody.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!